Search results
Results from the WOW.Com Content Network
Microscopic colitis refers to two related medical conditions which cause diarrhea: collagenous colitis and lymphocytic colitis. [ 2 ] [ 3 ] Both conditions are characterized by the presence of chronic non-bloody watery diarrhea , normal appearances on colonoscopy and characteristic histopathology findings of inflammatory cells.
No definite cause has been determined. The peak incidence of lymphocytic colitis is in persons over age 50; the disease affects twice as many women as men. [3] Some reports have implicated long-term usage of NSAIDs, proton pump inhibitors, and selective serotonin reuptake inhibitors, and other drugs.
Collagenous colitis is an inflammatory condition of the colon. Together with the related condition lymphocytic colitis, it is a subtype of microscopic colitis, which is characterized by inflammation that specifically affects the colon (i.e. colitis), and a clinical presentation that involves watery diarrhea but a lack of rectal bleeding.
Some 17,000 people in the UK are diagnosed with microscopic colitis - a debilitating condition which leads to inflammation of the large bowel and can cause symptoms including stomach pain, fatigue ...
For premium support please call: 800-290-4726 more ways to reach us
The signs and symptoms of colitis are quite variable and dependent on the cause of the given colitis and factors that modify its course and severity. [2]Common symptoms of colitis may include: mild to severe abdominal pains and tenderness (depending on the stage of the disease), persistent hemorrhagic diarrhea with pus either present or absent in the stools, fecal incontinence, flatulence ...
Clostridioides difficile, also known more commonly as C. diff, accounts for 10 to 20% of antibiotic-associated diarrhea cases, because the antibiotics administered for the treatment of certain disease processes such as inflammatory colitis also inadvertently kill a large portion of the gut flora, the normal flora that is usually present within the bowel.
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.